These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A severe case of bevacizumab-induced thrombotic microangiopathy.
    Author: Bektas M, Samancı NS, Cokgezer S, Keskin D, Demirelli FH.
    Journal: J Oncol Pharm Pract; 2019 Oct; 25(7):1754-1757. PubMed ID: 30253727.
    Abstract:
    Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.
    [Abstract] [Full Text] [Related] [New Search]